Stock listing
OTC:IOTCF Innovotech Inc. Stock
US listing (OTC) of Innovotech Inc. · home listing TSXV:IOT
Follow Innovotech Inc. into a list and get an email when it puts out news.
Home listing price · TSXV:IOT
$0.07 CAD 0.00 (0.0%)
Close on Nov 19, 2026 · This listing has no price on 6ix; the price shown is the home listing's, TSXV:IOT
- Day range
- $0.07 – $0.07 CADNov 19, 2026
- Volume
- 16,000 sharesNov 19, 2026
- Market cap
- $3.81M CADAt the close on Nov 19, 2026 · price × 54.44M shares outstanding
- 52-week range
- $0.06 – $0.29 CADLowest and highest trades, Nov 20, 2025 – Nov 19, 2026
- Traded on an average day
- $1,995 CADMedian day 0 shares · 38 days with no trades · last 3 months, Aug 19, 2026 – Nov 19, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| TSXV:IOT · Home | $0.07 CAD | 0.00 (0.0%) | 16,000 | $0.07 | $0.07 | $0.07 | $0.07 | Close on Nov 19, 2026 |
Daily closes
Last 3 months, Aug 19, 2026 – Nov 19, 2026 · TSXV:IOT · CAD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.07 | 0.00 | 0.0% | $0.07 | $0.07 | $0.07 | 16,000 | |
| $0.07 | +0.005 | +7.7% | $0.07 | $0.07 | $0.065 | 87,400 | |
| $0.065 | -0.025 | -27.8% | $0.09 | $0.09 | $0.065 | 326,055 | |
| $0.09 | 0.00 | 0.0% | $0.09 | $0.09 | $0.09 | 0 | |
| $0.09 | +0.01 | +12.5% | $0.08 | $0.09 | $0.07 | 212,700 | |
| $0.08 | 0.00 | 0.0% | $0.08 | $0.08 | $0.08 | 30,000 | |
| $0.08 | +0.02 | +33.3% | $0.07 | $0.08 | $0.07 | 163,000 | |
| $0.06 | 0.00 | 0.0% | $0.06 | $0.06 | $0.06 | 0 | |
| $0.06 | 0.00 | 0.0% | $0.06 | $0.06 | $0.06 | 0 | |
| $0.06 | 0.00 | 0.0% | $0.06 | $0.06 | $0.06 | 0 | |
| $0.06 | -0.01 | -14.3% | $0.06 | $0.06 | $0.06 | 10,000 | |
| $0.07 | 0.00 | 0.0% | $0.07 | $0.07 | $0.07 | 97,100 | |
| $0.07 | 0.00 | 0.0% | $0.07 | $0.07 | $0.07 | 0 | |
| $0.07 | 0.00 | 0.0% | $0.07 | $0.07 | $0.07 | 1,700 | |
| $0.07 | 0.00 | 0.0% | $0.07 | $0.07 | $0.07 | 0 | |
| $0.07 | 0.00 | 0.0% | $0.07 | $0.07 | $0.07 | 0 | |
| $0.07 | 0.00 | 0.0% | $0.07 | $0.07 | $0.07 | 0 | |
| $0.07 | 0.00 | 0.0% | $0.07 | $0.07 | $0.07 | 0 | |
| $0.07 | 0.00 | 0.0% | $0.07 | $0.07 | $0.07 | 0 | |
| $0.07 | 0.00 | 0.0% | $0.07 | $0.07 | $0.07 | 0 | |
| $0.07 | 0.00 | 0.0% | $0.07 | $0.07 | $0.07 | 4,500 | |
| $0.07 | 0.00 | 0.0% | $0.07 | $0.07 | $0.07 | 0 | |
| $0.07 | 0.00 | 0.0% | $0.07 | $0.07 | $0.07 | 0 | |
| $0.07 | 0.00 | 0.0% | $0.07 | $0.07 | $0.07 | 0 | |
| $0.07 | 0.00 | 0.0% | $0.07 | $0.07 | $0.07 | 0 | |
| $0.07 | 0.00 | 0.0% | $0.07 | $0.07 | $0.07 | 0 | |
| $0.07 | 0.00 | 0.0% | $0.07 | $0.07 | $0.07 | 0 | |
| $0.07 | 0.00 | 0.0% | $0.07 | $0.07 | $0.07 | 0 | |
| $0.07 | 0.00 | 0.0% | $0.07 | $0.07 | $0.07 | 0 | |
| $0.07 | 0.00 | 0.0% | $0.07 | $0.07 | $0.07 | 4,000 | |
| $0.07 | 0.00 | 0.0% | $0.07 | $0.07 | $0.07 | 0 | |
| $0.07 | 0.00 | 0.0% | $0.07 | $0.07 | $0.07 | 0 | |
| $0.07 | 0.00 | 0.0% | $0.07 | $0.07 | $0.07 | 124,900 | |
| $0.07 | 0.00 | 0.0% | $0.07 | $0.07 | $0.07 | 0 | |
| $0.07 | 0.00 | 0.0% | $0.07 | $0.07 | $0.07 | 166,300 | |
| $0.07 | 0.00 | 0.0% | $0.07 | $0.07 | $0.07 | 0 | |
| $0.07 | 0.00 | 0.0% | $0.07 | $0.07 | $0.07 | 0 | |
| $0.07 | 0.00 | 0.0% | $0.07 | $0.07 | $0.07 | 0 | |
| $0.07 | 0.00 | 0.0% | $0.07 | $0.07 | $0.07 | 0 | |
| $0.07 | -0.01 | -12.5% | $0.07 | $0.07 | $0.07 | 35,500 | |
| $0.08 | 0.00 | 0.0% | $0.08 | $0.08 | $0.08 | 0 | |
| $0.08 | 0.00 | 0.0% | $0.08 | $0.08 | $0.08 | 0 | |
| $0.08 | 0.00 | 0.0% | $0.08 | $0.08 | $0.08 | 0 | |
| $0.08 | 0.00 | 0.0% | $0.08 | $0.08 | $0.08 | 0 | |
| $0.08 | 0.00 | 0.0% | $0.08 | $0.08 | $0.08 | 0 | |
| $0.08 | 0.00 | 0.0% | $0.08 | $0.08 | $0.08 | 0 | |
| $0.08 | 0.00 | 0.0% | $0.08 | $0.08 | $0.08 | 25,000 | |
| $0.08 | +0.01 | +14.3% | $0.08 | $0.08 | $0.08 | 55,000 | |
| $0.07 | 0.00 | 0.0% | $0.07 | $0.07 | $0.07 | 0 | |
| $0.07 | 0.00 | 0.0% | $0.07 | $0.07 | $0.07 | 0 | |
| $0.07 | 0.00 | 0.0% | $0.08 | $0.08 | $0.07 | 9,000 | |
| $0.07 | -0.01 | -12.5% | $0.08 | $0.08 | $0.07 | 26,400 | |
| $0.08 | 0.00 | 0.0% | $0.08 | $0.08 | $0.08 | 0 | |
| $0.08 | 0.00 | 0.0% | $0.08 | $0.08 | $0.08 | 16,000 | |
| $0.08 | 0.00 | 0.0% | $0.08 | $0.08 | $0.08 | 9,000 | |
| $0.08 | 0.00 | 0.0% | $0.08 | $0.08 | $0.08 | 50,000 | |
| $0.08 | 0.00 | 0.0% | $0.08 | $0.08 | $0.08 | 0 | |
| $0.08 | -0.01 | -11.1% | $0.08 | $0.08 | $0.08 | 1,000 | |
| $0.09 | +0.01 | +12.5% | $0.09 | $0.09 | $0.09 | 10,000 | |
| $0.08 | 0.00 | 0.0% | $0.08 | $0.08 | $0.08 | 0 | |
| $0.08 | 0.00 | 0.0% | $0.08 | $0.08 | $0.08 | 4,000 | |
| $0.08 | 0.00 | 0.0% | $0.08 | $0.08 | $0.08 | 55,000 | |
| $0.08 | 0.00 | 0.0% | $0.08 | $0.08 | $0.08 | 0 | |
| $0.08 | +0.01 | +14.3% | $0.08 | $0.08 | $0.08 | 2,000 | |
| $0.07 | -0.01 | -12.5% | $0.08 | $0.08 | $0.07 | 213,000 |
- Ticker
- OTC:IOTCF
- Asset type
- Stock
- Sector
- Health care
- Industry
- Diagnostics & research services
- Exchange
- OTC
- Currency
- USD
What changed lately
Latest news release · Nov 10, 2026
Innovotech Reports Third Quarter 2026 Results
Latest news
Innovotech Reports Third Quarter 2026 Results
Nov 10, 2026
Closed $0.08 (+33.3%) on Nov 11, 2026
Innovotech Launches Streak Scientific to Supply Microbiology Culture Media and Laboratory Supplies to Canadian Laboratories
Nov 10, 2026
Closed $0.08 (+33.3%) on Nov 11, 2026
Innovotech Inc. Signs National Distribution Agreement with Healthmark to Bring InnovoTEST™ Hazardous Drug Wipe Testing Kits to Pharmacies Across Canada
Nov 3, 2026
Closed $0.07 (0.0%) on Nov 4, 2026
Innovotech Inc. Establishes New Banking Partnership with ATB Financial, Securing $600,000 in Credit Facilities to Support Growth
Oct 29, 2026
Closed $0.07 (0.0%) on Oct 30, 2026
Innovotech Inc. Reports Q2 2026 Financial Results
Aug 18, 2026
Closed $0.07 (-12.5%) on Aug 19, 2026
Innovotech Inc. Launches of InnovoTEST(TM) Hazardous Drug Wipe Testing Kits to Support Pharmacy Compliance and Healthcare Worker Safety
Aug 13, 2026
Closed $0.09 (0.0%) on Aug 14, 2026
Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing
Jun 26, 2026
Closed $0.10 (0.0%) on Jun 26, 2026
Issued by another party
Innovotech Inc. to Present at the Life Sciences Investor Forum on June 25th
Jun 24, 2026
Closed $0.10 (0.0%) on Jun 24, 2026
Innovotech Inc. Announces CFO Transition and Reports 2026 Annual General Meeting Result
Jun 16, 2026
Closed $0.11 (+10.0%) on Jun 17, 2026
Innovotech Inc. Receives Support to Develop Antimicrobial Testing Services and Product Enhancements
May 13, 2026
Closed $0.13 (+8.3%) on May 14, 2026
Innovotech Inc. on 6ix
- Sector
- Health care
- Industry
- Diagnostics & research services
- News releases
- 17 in the last 12 months · 92 in all · newest Nov 10, 2026 · oldest 2017
- Decks
- 6 decks · latest May 2025
Where Innovotech Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| TSXV:IOT · Home listing | TSXV | Canada | CAD |
| OTC:IOTCF · This page | OTC | United States | USD |
| Cboe Canada:IOT | Cboe Canada | Canada | CAD |
Valuation
EV/sales 1.0× against a median of 4.5×: 3rd lowest of 8 Diagnostics & research services companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 19, 2026
- Enterprise value
- $3.60M CAD
- P/E
- Loss
- EV/sales
- 1.0×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 1.5×
- Gross margin
- 39.4%
- Operating margin
- −21.4%
- Net margin
- −21.1%
- Debt to equity
- 0.1×
- Beta vs S&P/TSX Composite
- 0.39
Diagnostics & research services: the 10 companies nearest in size, of 302 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Innovotech Inc. · TSXV:IOT | US$2.66M | US$2.51M | n/a | 1.0× | n/a | 1.5× | −21.1% | 0.1× | 0.39 |
| SDS Optic Spolka Akcyjna · NEWCONNECT:SDS | US$3.82M | US$3.57M | n/a | 13.7× | n/a | 11.8× | −269.4% | 0.0× | n/a |
| genXone SA · NEWCONNECT:GX1 | US$3.47M | US$2.77M | n/a | 4.5× | 18.6× | 1.9× | −67.9% | 0.0× | n/a |
| Telo Genomics Corp. · TSXV:TELO | US$2.80M | US$2.12M | n/a | n/a | n/a | n/a | n/a | n/a | 0.04 |
| Advanced Biomed Inc. · NASDAQ:ADVB | US$2.73M | US$3.12M | 0.5× | 12.2× | n/a | 0.2× | n/a | 0.1× | 0.35 |
| Qlife Holding AB · OMXSTO:QLIFE | US$2.49M | US$2.88M | n/a | 34.1× | n/a | 9.6× | n/a | 3.1× | n/a |
| Physiomics PLC · LSE:PYC | US$2.46M | US$1.91M | n/a | 1.6× | n/a | 3.6× | −74.1% | 0.0× | n/a |
| 20/20 BioLabs, Inc. · NASDAQ:AIDX | US$2.10M | −US$1.01M | n/a | −0.5× | n/a | 3.4× | −317.8% | 0.9× | 1.41 |
| Bluejay Diagnostics, Inc. · NASDAQ:BJDX | US$1.90M | −US$5.43M | n/a | n/a | n/a | 0.3× | n/a | 0.0× | 1.71 |
| Accustem Sciences Inc · OTC:ACUT | US$1.90M | US$1.88M | n/a | n/a | n/a | n/a | n/a | n/a | 0.19 |
| InVitro International · OTC:IVRO | US$1.87M | US$644,260 | 29.6× | 0.8× | 14.0× | 1.1× | 8.2% | 0.0× | 0.17 |
| Median of the others | US$2.47M | US$2.02M | 15.1× | 4.5× | 16.3× | 2.6× | −74.1% | 0.0× | 0.27 |
Team and board
Officers
| Officer | Role |
|---|---|
| Craig Milne | CEO, President, Director |
| Craig Kalvin | Chief Financial Officer |
| Jodi McDonald | Chief Operating Officer |
| Greg Young | VP Corporate Services |
| Rod Szarka | Chief Commercial Officer |
Board
| Director | Role |
|---|---|
| James Timourian | Director, Board Chair |
| Arden Tse | Director |
| Brad Clark | Director |
| Craig Milne | CEO, President, Director |
| David Tam | Director |
| Julie Wright | Director |
| Karen Farkas | Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Quarter to Sep 30, 2026 | Nov 9, 2026 · After close | 0.0% |
| Q2 2023 | Aug 15, 2023 · After close | −12.5% |
| Q1 2023 | May 23, 2023 · After close | 0.0% |
| Q3 2021 | Nov 16, 2021 | −9.5% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (May 2025) | Investor deck | 18 slides | May 2025 |
| Investor Presentation (May 2022) | Investor deck | 16 slides | May 2022 |
| Investor Presentation (June 2021) | Investor deck | 16 slides | June 2021 |
| Investor Presentation (April 2021) | Investor deck | 15 slides | April 2021 |
| Investor Presentation (December 2020) | Investor deck | 16 slides | December 2020 |
| Fact Sheet (June 2018) | Fact sheet | 2 slides | June 2018 |
Financings
| Raise | Date | In US dollars |
|---|---|---|
| Unsecured convertible debenture Announced: up to C$200,000 Insiders: A related party is expected to be the single participant in the Offering Use of proceeds: Expand analytical services through Keystone Labs, including lab equipment for hazardous drug testing and further analytical capabilities | Oct 16, 2025 | US$142,369 |
| Warrant exercise of share purchase warrants Announced: C$65,385 · Warrants at C$0.17 Insiders: A related party intends to exercise the warrants | Oct 16, 2025 | US$46,544 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in CAD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.53M | 2.19M | 1.18M | 1.13M | 1.48M | 1.19M | 986.2K | 826.9K | 990.3K | 1.01M |
| Cost of revenue | 2.14M | 1.08M | 700.8K | 346.3K | 363.2K | 326.5K | 291.1K | 220.6K | 290.6K | 272.3K |
| Gross profit | 2.40M | 1.11M | 481.8K | 779.5K | 1.12M | 866.9K | 695.1K | 606.3K | 699.8K | 733.3K |
| Research and development | 523.2K | 276.7K | 216.5K | 111.0K | 34.9K | 48.0K | 23.4K | 39.1K | 67.5K | 148.6K |
| Selling, general and administrative | 2.27M | 1.01M | 686.4K | 832.5K | 815.8K | 760.5K | 718.2K | 697.5K | 608.0K | 498.6K |
| Operating income | 23.9K | 48.1K | -379.7K | -140.4K | 268.0K | 99.3K | -19.9K | -127.0K | 36.0K | 86.1K |
| Depreciation and amortization | 142.8K | 61.6K | 78.3K | 114.2K | 70.9K | 17.9K | 13.3K | 15.4K | 16.8K | 19.4K |
| EBITDA | 166.8K | 109.8K | -301.4K | -26.3K | 338.8K | 117.3K | -6.60K | -111.6K | 52.8K | 105.5K |
| Interest expense | 33.0K | 9.96K | 557 | 5.02K | 4.38K | 3.00K | 6.00K | 650 | 0 | 0 |
| Income before tax | 88.6K | 214.8K | -157.6K | -136.5K | 367.1K | 106.3K | -48.8K | -127.6K | 753.4K | -215.5K |
| Income tax | 0 | 0 | ||||||||
| Net income | 94.4K | 224.7K | -157.6K | -136.5K | 367.1K | 106.3K | -48.8K | -127.6K | 753.4K | -215.5K |
| Earnings per share, basic | 0.00 | 0.00 | -0.00 | -0.00 | 0.01 | 0.00 | -0.00 | -0.00 | 0.02 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 1.62M | 725.4K | 160.5K | 469.1K | 422.4K | 530.1K | 96.7K | 28.8K | 324.5K | 33.2K |
| Short-term investments | 0 | 68.1K | 81.6K | 72.2K | 20.0K | |||||
| Receivables | 507.6K | 536.1K | 204.3K | 184.9K | 358.3K | 136.9K | 101.2K | 147.8K | 87.8K | 176.3K |
| Inventory | 185.5K | 128.4K | 70.0K | 42.2K | 59.8K | 38.9K | 21.5K | 28.1K | 38.7K | 36.3K |
| Current assets | 3.02M | 1.68M | 565.1K | 826.0K | 993.5K | 752.7K | 224.8K | 211.4K | 459.0K | 252.9K |
| Property, plant and equipment | 229.4K | 69.7K | 50.1K | 60.9K | 68.3K | 72.4K | ||||
| Total assets | 4.43M | 3.22M | 1.22M | 1.22M | 1.43M | 822.4K | 274.9K | 272.3K | 527.3K | 325.3K |
| Accounts payable | 376.3K | 286.9K | 104.2K | 83.7K | 73.3K | 65.3K | 217.9K | 498.1K | ||
| Current liabilities | 522.1K | 421.0K | 175.5K | 165.3K | 219.0K | 157.5K | 76.8K | 178.9K | 345.8K | 1.54M |
| Long-term debt | 160.5K | 20.0K | 100.0K | |||||||
| Total liabilities | 784.7K | 596.8K | 217.9K | 165.3K | 256.0K | 177.5K | 176.8K | 178.9K | 345.8K | 1.54M |
| Shareholders' equity | 3.60M | 2.57M | 930.6K | 1.06M | 1.18M | 645.0K | 98.1K | 93.5K | 181.5K | -1.22M |
| Shares outstanding | 54.4M | 49.7M | 39.0M | 38.9M | 38.9M | 38.3M | 36.2M | 36.2M | 33.7M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -62.4K | -81.6K | -228.1K | 208.4K | 25.0K | 175.2K | 76.3K | -280.7K | -158.7K | 2.32K |
| Capital spending | -471.5K | -202.3K | -42.9K | -71.5K | -60.1K | -37.7K | -2.44K | -9.32K | -13.7K | -13.7K |
| Free cash flow | -533.9K | -283.9K | -271.0K | 136.9K | -35.1K | 137.6K | 73.9K | -290.1K | -172.4K | -11.3K |
| Cash from investing | -60.1K | -37.7K | -2.44K | -9.32K | -11.6K | 4.00K | ||||
| Cash from financing | 878.0K | 1.14M | -37.6K | -90.2K | -72.6K | 305.9K | -6.00K | -5.65K | 461.6K | -5.59K |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Share buybacks | 528.0K | 528.0K | ||||||||
| Change in cash | 894.2K | 564.9K | -308.5K | 46.6K | -107.7K | 433.5K | 67.9K | -295.7K | 291.4K | 726 |
Cap table
Built by 6ix from Innovotech Inc.’s releases · as of Oct 16, 2025
- Common shares
- 54,438,235
- Fully diluted
- 54,438,235
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 54,438,235 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 54,438,235 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Arden Tse | Director · Since at least Jun 16, 2026 |
| Brad Clark | Director · Since at least Jun 16, 2026 |
| Craig Kalvin | Chief Financial Officer · Since at least Jun 16, 2026 |
| Craig Milne | CEO, President, Director · Since at least Oct 29, 2026 |
| David Tam | Director · Since at least Jun 16, 2026 |
| Greg Young | VP Corporate Services · Since at least Jun 24, 2026 |
| James Timourian | Director, Board Chair · Since at least Jun 16, 2026 |
| Jodi McDonald | Chief Operating Officer · Since at least Feb 5, 2026 |
| Julie Wright | Director · Since at least Jun 16, 2026 |
| Karen Farkas | Director · Since at least Jun 16, 2026 |
All 12 people
| Person | Seat |
|---|---|
| Patricia Nadworny | Chief Scientific Officer · May 8, 2025 – Nov 4, 2026 · Past |
| Rod Szarka | Chief Commercial Officer · Since at least Feb 5, 2026 |
Log in to ask 6ix AI your own questions about Innovotech Inc.